mitoxantrone has been researched along with Acute Relapsing Multiple Sclerosis in 86 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The study's aim was to compare the efficacy and safety of intravenous cyclophosphamide (CTX) and mitoxantrone (MITO) as second-line therapy in a clinical sample of active relapsing-remitting (RR) or secondary-progressive (SP) multiple sclerosis subjects." | 9.13 | Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety. ( Amato, MP; Hakiki, B; Portaccio, E; Siracusa, G; Sorbi, S; Zipoli, V, 2008) |
| "Mitoxantrone (MX) has been shown to be moderately effective in reducing the clinical outcome measures of disease activity in multiple sclerosis (MS) patients." | 8.89 | Mitoxantrone for multiple sclerosis. ( Capra, R; Comi, G; Martinelli Boneschi, F; Rovaris, M; Vacchi, L, 2013) |
| "The accumulated Class III and IV evidence suggests an increased incidence of systolic dysfunction and therapy-related acute leukemia (TRAL) with mitoxantrone therapy." | 8.86 | Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. ( Gronseth, G; Marriott, JJ; Miyasaki, JM; O'Connor, PW, 2010) |
| "Mitoxantrone is approved by several health authorities for treatment of active forms of relapsing-remitting or secondary progressive multiple sclerosis (SPMS)." | 8.83 | Therapeutic role of mitoxantrone in multiple sclerosis. ( Hartung, HP; Kieseier, BC; Neuhaus, O, 2006) |
| "MEDLINE (1966-present) and the Cochrane Central Register of Controlled Trials (1994-present) were searched for relevant randomized, blinded, controlled clinical trials using the terms mitoxantrone, Novantrone, and multiple sclerosis." | 8.83 | Management of worsening multiple sclerosis with mitoxantrone: a review. ( Fox, EJ, 2006) |
| "The approval by the FDA of four immunomodulators (three IFNs and glatiramer acetate) and one immunosuppressant (mitoxantrone; Novantrone) for the treatment of multiple sclerosis is definitely the most important progress in this field since the first description of the disease > 150 years ago." | 8.82 | A comparison of the benefits of mitoxantrone and other recent therapeutic approaches in multiple sclerosis. ( Gonsette, RE, 2004) |
| "Six monthly courses of mitoxantrone were approved in France in 2003 for patients with highly active multiple sclerosis (MS)." | 8.12 | Ten-year follow-up after mitoxantrone induction for early highly active relapsing-remitting multiple sclerosis: An observational study of 100 consecutive patients. ( Edan, G; Kerbrat, A; Le Corre, G; Le Page, E; Le Port, D; Lefort, M; Leray, E; Michel, L; Rizzato, C, 2022) |
| "Mitoxantrone (MTX) has been used as an effective disease modifying treatment (DMT) in multiple sclerosis (MS)." | 7.96 | Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone. ( Foo, EC; Ford, HL; Lily, O; Russell, M, 2020) |
| "Our study aimed to describe safety and neurological impact of alemtuzumab as last-line rescue therapy in aggressive multiple sclerosis (MS) patients, previously treated by Mitoxantrone (MITOX)." | 7.81 | Alemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational study. ( Cardiet, I; Deburghgraeve, V; Edan, G; Le Page, E; Leray, E; Lester, MA, 2015) |
| "The objective in this paper is to compare the cumulative incidence and incidence density of therapy-related acute myeloid leukaemia in two cohorts of patients with multiple sclerosis treated with mitoxantrone, and with previously reported data in the literature." | 7.75 | Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required. ( Abellán, I; Belenguer, A; Boscá, I; Casanova, B; Coret, F; Fernández, P; Magraner, MJ; Mallada, J; Montalbán, X; Pascual, AM; Sanz, MA; Sempere, AP; Téllez, N, 2009) |
| "Mitoxantrone is an approved drug for patients with worsening relapsing-remitting, secondary progressive and progressive relapsing multiple sclerosis (MS)." | 7.73 | Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone. ( Goffette, S; Morandini, E; Sindic, CJ; van Pesch, V; Vanoverschelde, JL, 2005) |
| "Azathioprine is an immunosuppressive and steroid-sparing purine analogue, used in the treatment of several autoimmune diseases." | 6.44 | Azathioprine in multiple sclerosis. ( Benedetti, MD; Invernizzi, P; Monaco, S; Poli, S, 2008) |
| "Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis (RENEW) was a 5-year, phase IV study in which the safety of Mitoxantrone was monitored in a patient cohort from the United States (US)." | 5.17 | Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study. ( Bock, D; Dangond, F; Jeffery, DR; Rivera, VM; Weinstock-Guttman, B, 2013) |
| "The study's aim was to compare the efficacy and safety of intravenous cyclophosphamide (CTX) and mitoxantrone (MITO) as second-line therapy in a clinical sample of active relapsing-remitting (RR) or secondary-progressive (SP) multiple sclerosis subjects." | 5.13 | Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety. ( Amato, MP; Hakiki, B; Portaccio, E; Siracusa, G; Sorbi, S; Zipoli, V, 2008) |
| "To evaluate the effects of mitoxantrone (Mx) in progressive multiple sclerosis (MS) on MRI." | 5.11 | Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial. ( Gonsette, R; Hartung, HP; Krapf, H; Morrissey, SP; Zenker, O; Zwingers, T, 2005) |
| "Therapy-related acute leukaemia (TRAL) is a significant concern, when considering treatment with mitoxantrone for multiple sclerosis (MS)." | 4.91 | Therapy-related acute leukaemia with mitoxantrone: four years on, what is the risk and can it be limited? ( Boggild, M; Brown, S; Ellis, R, 2015) |
| "Mitoxantrone (MX) has been shown to be moderately effective in reducing the clinical outcome measures of disease activity in multiple sclerosis (MS) patients." | 4.89 | Mitoxantrone for multiple sclerosis. ( Capra, R; Comi, G; Martinelli Boneschi, F; Rovaris, M; Vacchi, L, 2013) |
| "The accumulated Class III and IV evidence suggests an increased incidence of systolic dysfunction and therapy-related acute leukemia (TRAL) with mitoxantrone therapy." | 4.86 | Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. ( Gronseth, G; Marriott, JJ; Miyasaki, JM; O'Connor, PW, 2010) |
| "MEDLINE (1966-present) and the Cochrane Central Register of Controlled Trials (1994-present) were searched for relevant randomized, blinded, controlled clinical trials using the terms mitoxantrone, Novantrone, and multiple sclerosis." | 4.83 | Management of worsening multiple sclerosis with mitoxantrone: a review. ( Fox, EJ, 2006) |
| "Mitoxantrone is approved by several health authorities for treatment of active forms of relapsing-remitting or secondary progressive multiple sclerosis (SPMS)." | 4.83 | Therapeutic role of mitoxantrone in multiple sclerosis. ( Hartung, HP; Kieseier, BC; Neuhaus, O, 2006) |
| "The approval by the FDA of four immunomodulators (three IFNs and glatiramer acetate) and one immunosuppressant (mitoxantrone; Novantrone) for the treatment of multiple sclerosis is definitely the most important progress in this field since the first description of the disease > 150 years ago." | 4.82 | A comparison of the benefits of mitoxantrone and other recent therapeutic approaches in multiple sclerosis. ( Gonsette, RE, 2004) |
| " On the 29th of October 2003, mitoxantrone was approved by the french health agency Afssaps (Agence française de sécurité sanitaire des produits de santé) for its use in the aggressive forms of multiple sclerosis (MS)." | 4.82 | [Aggressive multiple sclerosis. Definition and specific therapeutic indication]. ( Edan, G, 2004) |
| "Six monthly courses of mitoxantrone were approved in France in 2003 for patients with highly active multiple sclerosis (MS)." | 4.12 | Ten-year follow-up after mitoxantrone induction for early highly active relapsing-remitting multiple sclerosis: An observational study of 100 consecutive patients. ( Edan, G; Kerbrat, A; Le Corre, G; Le Page, E; Le Port, D; Lefort, M; Leray, E; Michel, L; Rizzato, C, 2022) |
| "Mitoxantrone (MTX) has been used as an effective disease modifying treatment (DMT) in multiple sclerosis (MS)." | 3.96 | Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone. ( Foo, EC; Ford, HL; Lily, O; Russell, M, 2020) |
| "Our study aimed to describe safety and neurological impact of alemtuzumab as last-line rescue therapy in aggressive multiple sclerosis (MS) patients, previously treated by Mitoxantrone (MITOX)." | 3.81 | Alemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational study. ( Cardiet, I; Deburghgraeve, V; Edan, G; Le Page, E; Leray, E; Lester, MA, 2015) |
| "The objective in this paper is to compare the cumulative incidence and incidence density of therapy-related acute myeloid leukaemia in two cohorts of patients with multiple sclerosis treated with mitoxantrone, and with previously reported data in the literature." | 3.75 | Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required. ( Abellán, I; Belenguer, A; Boscá, I; Casanova, B; Coret, F; Fernández, P; Magraner, MJ; Mallada, J; Montalbán, X; Pascual, AM; Sanz, MA; Sempere, AP; Téllez, N, 2009) |
| "Mitoxantrone is an approved drug for patients with worsening relapsing-remitting, secondary progressive and progressive relapsing multiple sclerosis (MS)." | 3.73 | Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone. ( Goffette, S; Morandini, E; Sindic, CJ; van Pesch, V; Vanoverschelde, JL, 2005) |
| "Mitoxantrone was approved by the French health authority (AFSAPPS) in October 2003 to treat patients with aggressive multiple sclerosis (MS)." | 2.73 | Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. ( Chaperon, J; Coustans, M; Edan, G; Le Page, E; Leray, E; Morrissey, SP; Taurin, G, 2008) |
| "Mitoxantrone has been approved by the FDA for worsening relapsing remitting and secondary progressive Multiple Sclerosis." | 2.72 | Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis. ( Boggild, M; Das, K; Jacob, A; Ramtahal, J, 2006) |
| "Mitoxantrone is an antineoplastic drug, recently approved for treatment of multiple sclerosis." | 2.72 | Mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis. ( Etemadifar, M; Hamzehloo, A, 2006) |
| " Dosing was continued at 5 mg/m2 every third month." | 2.71 | A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging. ( Burdette, J; Chepuri, N; Durden, D; Jeffery, DR, 2005) |
| "In this article, we review the potential adverse effects and recommended laboratory studies as part of the monitoring strategy following initiation of various first generation DMTs and their recently approved versions." | 2.53 | Update on monitoring and adverse effects of first generation disease modifying therapies and their recently approved versions in relapsing forms of multiple sclerosis. ( Cano, CA; Dubey, D; Stüve, O, 2016) |
| " Regarding 'patients with adverse events', no data were available for all comparisons to make fair inferences." | 2.49 | A network meta-analysis of randomized controlled trials for comparing the effectiveness and safety profile of treatments with marketing authorization for relapsing multiple sclerosis. ( Bakalos, G; Doxani, C; Grigoriadis, N; Hadjigeorgiou, GM; Miligkos, M; Mprotsis, T; Papadimitriou, D; Ziakas, P; Zintzaras, E, 2013) |
| "Azathioprine is an immunosuppressive and steroid-sparing purine analogue, used in the treatment of several autoimmune diseases." | 2.44 | Azathioprine in multiple sclerosis. ( Benedetti, MD; Invernizzi, P; Monaco, S; Poli, S, 2008) |
| "Mitoxantrone (MX) has been approved by the Food and Drug Administration (FDA) for the treatment of patients with worsening relapsing-remitting (RR) or secondary progressive (SP) multiple sclerosis (MS)." | 2.42 | Mitoxantrone in progressive multiple sclerosis: when and how to treat? ( Gonsette, RE, 2003) |
| "Mitoxantrone is an anthracenedione anti-neoplastic agent that has recently been shown to be effective in ameliorating disease activity in multiple sclerosis (MS) as indicated by clinical and MRI data." | 2.40 | [Mitoxantrone (Novantron) in therapy of severe multiple sclerosis. A retrospective study of 15 patients]. ( Cursiefen, S; Flachenecker, P; Rieckmann, P; Toyka, KV, 1999) |
| "Mitoxantrone (MITOX) has been used to treat patients with aggressive multiple sclerosis (MS) for decades." | 1.48 | Clinical follow-up of 411 patients with relapsing and progressive multiple sclerosis 10 years after discontinuing mitoxantrone treatment: a real-life cohort study. ( Chartier, N; Dahan, C; Debouverie, M; Epstein, J; Guillemin, F; Mathey, G; Michaud, M; Pittion-Vouyovitch, S; Soudant, M, 2018) |
| " Continuing research is needed to establish its efficacy and safety profile in a multinational collaboration with careful follow-up of adverse events." | 1.40 | Safety and efficacy of mitoxantrone in pediatric patients with aggressive multiple sclerosis. ( Abtahi, SH; Afzali, P; Etemadifar, M; Fereidan-Esfahani, M; Murray, RT; Nourian, SM; Ramagopalan, SV, 2014) |
| "Mitoxantrone (MTX) is an immunosuppressive drug approved for multiple sclerosis (MS) treatment." | 1.36 | Comparative study of mitoxantrone efficacy profile in patients with relapsing-remitting and secondary progressive multiple sclerosis. ( Comi, G; Esposito, F; Martinelli Boneschi, F; Martinelli, V; Moiola, L; Radaelli, M; Rocca, MA; Rodegher, M; Sormani, MP, 2010) |
| "Nine anaphylactoid reactions, two severe, were reported." | 1.35 | Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. ( Jensen, PE; Koch-Henriksen, N; Oturai, AB; Petersen, T; Sellebjerg, F; Sorensen, PS, 2009) |
| "We report the first case of chronic myeloid leukemia (CML) in a patient with multiple sclerosis (MS) diagnosed within two years of receiving mitoxantrone therapy." | 1.35 | Chronic myeloid leukemia associated with mitoxantrone treatment in a patient with MS. ( Rammal, M; Sadiq, SA; Sara, G, 2008) |
| "On mitoxantrone treatment there was a considerable neurologic recovery." | 1.34 | 3-methylcrotonyl-CoA carboxylase deficiency and severe multiple sclerosis. ( Andersen, O; Darin, N; Holme, E; Holmgren, D; Wiklund, LM, 2007) |
| "Mitoxantrone (MTX) is an antineoplastic agent approved for treatment of secondary progressive and rapidly worsening relapsing-remitting multiple sclerosis (MS)." | 1.34 | Mitoxantrone treatment in multiple sclerosis: a 5-year clinical and MRI follow-up. ( Borriello, G; Buttinelli, C; Clemenzi, A; Denaro, F; Fieschi, C; Pozzilli, C, 2007) |
| " However, these approaches will not take into account the possible dose-response relationship on each endpoint, and therefore are less specific and may have lower power." | 1.33 | Multiplicity adjustment for multiple endpoints in clinical trials with multiple doses of an active treatment. ( Capizzi, T; Luo, X; Quan, H, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.16) | 18.2507 |
| 2000's | 51 (59.30) | 29.6817 |
| 2010's | 31 (36.05) | 24.3611 |
| 2020's | 3 (3.49) | 2.80 |
| Authors | Studies |
|---|---|
| Lefort, M | 1 |
| Le Corre, G | 1 |
| Le Page, E | 7 |
| Rizzato, C | 1 |
| Le Port, D | 1 |
| Michel, L | 1 |
| Kerbrat, A | 1 |
| Leray, E | 6 |
| Edan, G | 9 |
| Foo, EC | 1 |
| Russell, M | 1 |
| Lily, O | 1 |
| Ford, HL | 1 |
| Fernández, Ó | 1 |
| Doshi, A | 1 |
| Chataway, J | 1 |
| Khamidulla, A | 1 |
| Kabdrakhmanova, G | 1 |
| Utepkaliyeva, A | 1 |
| Darin, D | 1 |
| Urasheva, Z | 1 |
| Chartier, N | 1 |
| Epstein, J | 1 |
| Soudant, M | 1 |
| Dahan, C | 1 |
| Michaud, M | 1 |
| Pittion-Vouyovitch, S | 3 |
| Guillemin, F | 1 |
| Debouverie, M | 3 |
| Mathey, G | 1 |
| Axelsson, M | 3 |
| Dubuisson, N | 1 |
| Novakova, L | 2 |
| Malmeström, C | 3 |
| Giovannoni, G | 1 |
| Lycke, J | 3 |
| Gnanapavan, S | 1 |
| Martinelli Boneschi, F | 2 |
| Vacchi, L | 2 |
| Rovaris, M | 1 |
| Capra, R | 1 |
| Comi, G | 3 |
| Filippini, G | 1 |
| Del Giovane, C | 1 |
| D'Amico, R | 1 |
| Di Pietrantonj, C | 1 |
| Beecher, D | 1 |
| Salanti, G | 1 |
| Rivera, VM | 1 |
| Jeffery, DR | 2 |
| Weinstock-Guttman, B | 1 |
| Bock, D | 1 |
| Dangond, F | 1 |
| Hadjigeorgiou, GM | 1 |
| Doxani, C | 1 |
| Miligkos, M | 1 |
| Ziakas, P | 1 |
| Bakalos, G | 1 |
| Papadimitriou, D | 1 |
| Mprotsis, T | 1 |
| Grigoriadis, N | 1 |
| Zintzaras, E | 1 |
| Etemadifar, M | 2 |
| Afzali, P | 1 |
| Abtahi, SH | 1 |
| Ramagopalan, SV | 1 |
| Nourian, SM | 1 |
| Murray, RT | 1 |
| Fereidan-Esfahani, M | 1 |
| Correale, J | 2 |
| Abad, P | 1 |
| Alvarenga, R | 1 |
| Alves-Leon, S | 1 |
| Armas, E | 1 |
| Barahona, J | 1 |
| Buzó, R | 1 |
| Corona, T | 1 |
| Cristiano, E | 1 |
| Gracia, F | 1 |
| Bonitto, JG | 1 |
| Macías, MA | 1 |
| Soto, A | 1 |
| Vizcarra, D | 1 |
| Freedman, MS | 3 |
| Salhofer-Polanyi, S | 1 |
| Leutmezer, F | 1 |
| Ellis, R | 1 |
| Brown, S | 1 |
| Boggild, M | 3 |
| Sedal, L | 1 |
| Wilson, IB | 1 |
| McDonald, EA | 1 |
| Mancardi, GL | 1 |
| Sormani, MP | 2 |
| Gualandi, F | 1 |
| Saiz, A | 1 |
| Carreras, E | 1 |
| Merelli, E | 1 |
| Donelli, A | 1 |
| Lugaresi, A | 1 |
| Di Bartolomeo, P | 1 |
| Rottoli, MR | 1 |
| Rambaldi, A | 1 |
| Amato, MP | 2 |
| Massacesi, L | 1 |
| Di Gioia, M | 1 |
| Vuolo, L | 1 |
| Currò, D | 1 |
| Roccatagliata, L | 1 |
| Filippi, M | 2 |
| Aguglia, U | 1 |
| Iacopino, P | 1 |
| Farge, D | 1 |
| Saccardi, R | 1 |
| Deburghgraeve, V | 1 |
| Lester, MA | 1 |
| Cardiet, I | 1 |
| Patejdl, R | 1 |
| Krohn, S | 1 |
| Murua Escobar, H | 1 |
| Zettl, UK | 1 |
| Öhrfelt, A | 1 |
| Heslegrave, A | 1 |
| Blennow, K | 2 |
| Zetterberg, H | 2 |
| Dubey, D | 1 |
| Cano, CA | 1 |
| Stüve, O | 1 |
| Invernizzi, P | 1 |
| Benedetti, MD | 1 |
| Poli, S | 1 |
| Monaco, S | 1 |
| Linker, RA | 1 |
| Kieseier, BC | 3 |
| Arnold, DL | 2 |
| Campagnolo, D | 2 |
| Panitch, H | 2 |
| Bar-Or, A | 2 |
| Dunn, J | 2 |
| Gazda, SK | 2 |
| Vollmer, T | 2 |
| Webb, UH | 1 |
| Sorensen, PS | 2 |
| Oturai, AB | 1 |
| Koch-Henriksen, N | 1 |
| Petersen, T | 1 |
| Jensen, PE | 1 |
| Sellebjerg, F | 1 |
| Reinsberger, C | 1 |
| Meuth, SG | 1 |
| Wiendl, H | 1 |
| Pascual, AM | 1 |
| Téllez, N | 1 |
| Boscá, I | 1 |
| Mallada, J | 1 |
| Belenguer, A | 1 |
| Abellán, I | 1 |
| Sempere, AP | 1 |
| Fernández, P | 1 |
| Magraner, MJ | 1 |
| Coret, F | 1 |
| Sanz, MA | 1 |
| Montalbán, X | 2 |
| Casanova, B | 1 |
| Calabrese, M | 1 |
| Mattisi, I | 1 |
| Rinaldi, F | 1 |
| Favaretto, A | 1 |
| Atzori, M | 1 |
| Bernardi, V | 1 |
| Barachino, L | 1 |
| Romualdi, C | 1 |
| Rinaldi, L | 1 |
| Perini, P | 1 |
| Gallo, P | 1 |
| Sazonov, DV | 1 |
| Malkova, NA | 1 |
| Bulatova, EV | 1 |
| Riabukhina, OV | 1 |
| van der Voort, LF | 1 |
| Gilli, F | 1 |
| Bertolotto, A | 1 |
| Knol, DL | 1 |
| Uitdehaag, BM | 1 |
| Polman, CH | 1 |
| Killestein, J | 1 |
| Bourdette, D | 1 |
| Whitham, R | 1 |
| Marriott, JJ | 1 |
| Miyasaki, JM | 1 |
| Gronseth, G | 1 |
| O'Connor, PW | 1 |
| Sailer, M | 1 |
| Launay, M | 1 |
| Lebrun, C | 2 |
| Giordana, E | 1 |
| Chanalet, S | 1 |
| Thomas, P | 1 |
| Esposito, F | 1 |
| Radaelli, M | 1 |
| Martinelli, V | 1 |
| Moiola, L | 1 |
| Rocca, MA | 2 |
| Rodegher, M | 1 |
| Sørensen, PS | 1 |
| Havla, J | 1 |
| Kümpfel, T | 1 |
| Hohlfeld, R | 1 |
| Augutis, K | 1 |
| Portelius, E | 1 |
| Brinkmalm, G | 1 |
| Andreasson, U | 1 |
| Gustavsson, MK | 1 |
| Mattsson, N | 1 |
| Gonsette, RE | 2 |
| Pericot, I | 1 |
| Río, J | 1 |
| Rovira, A | 1 |
| Castellà, MD | 1 |
| Tintoré, M | 1 |
| Hartung, HP | 3 |
| Flachenecker, P | 3 |
| Rieckmann, P | 5 |
| Vandenberghe, N | 1 |
| Morrissey, SP | 3 |
| Anxionnat, R | 1 |
| Vespignani, H | 2 |
| Chen, X | 1 |
| Luo, X | 2 |
| Capizzi, T | 2 |
| Csépány, T | 2 |
| Bereczki, D | 2 |
| Rush, C | 1 |
| Amengual, A | 1 |
| Goicochea, MT | 1 |
| Goffette, S | 1 |
| van Pesch, V | 1 |
| Vanoverschelde, JL | 1 |
| Morandini, E | 1 |
| Sindic, CJ | 1 |
| Burks, JS | 1 |
| Quan, H | 1 |
| Chepuri, N | 1 |
| Durden, D | 1 |
| Burdette, J | 1 |
| Benesova, Y | 1 |
| Stourac, P | 1 |
| Beranek, M | 1 |
| Kadanka, Z | 1 |
| Neuhaus, O | 1 |
| Krapf, H | 1 |
| Zenker, O | 1 |
| Zwingers, T | 1 |
| Gonsette, R | 1 |
| Fox, RJ | 1 |
| Bethoux, F | 1 |
| Goldman, MD | 1 |
| Cohen, JA | 1 |
| Taurin, G | 2 |
| Coustans, M | 2 |
| Chaperon, J | 2 |
| Hamzehloo, A | 1 |
| Fox, EJ | 1 |
| Alchaar, H | 1 |
| Candito, M | 1 |
| Bourg, V | 1 |
| Chatel, M | 1 |
| Ramtahal, J | 1 |
| Jacob, A | 1 |
| Das, K | 1 |
| Mezei, Z | 1 |
| Csiba, L | 1 |
| Darin, N | 1 |
| Andersen, O | 1 |
| Wiklund, LM | 1 |
| Holmgren, D | 1 |
| Holme, E | 1 |
| Cocco, E | 1 |
| Marchi, P | 1 |
| Sardu, C | 1 |
| Russo, P | 1 |
| Paolillo, A | 1 |
| Mascia, M | 1 |
| Solla, M | 1 |
| Frau, J | 1 |
| Lorefice, L | 1 |
| Massole, S | 1 |
| Floris, G | 1 |
| Marrosu, M | 1 |
| Taillandier, L | 1 |
| Louis, S | 1 |
| Wasay, M | 1 |
| Ali, S | 1 |
| Khatri, IA | 1 |
| Hassan, A | 1 |
| Asif, M | 1 |
| Zakiullah, N | 1 |
| Ahmed, A | 1 |
| Malik, A | 1 |
| Khealani, B | 1 |
| Haq, A | 1 |
| Fredrikson, S | 1 |
| Gold, R | 1 |
| Komori, M | 1 |
| Tanaka, M | 1 |
| Muramoto, E | 1 |
| Ohno, M | 1 |
| Matsumoto, R | 1 |
| Murase, N | 1 |
| Kitagawa, N | 1 |
| Saida, T | 1 |
| Zipoli, V | 1 |
| Portaccio, E | 1 |
| Hakiki, B | 1 |
| Siracusa, G | 1 |
| Sorbi, S | 1 |
| Buttinelli, C | 1 |
| Clemenzi, A | 1 |
| Borriello, G | 1 |
| Denaro, F | 1 |
| Pozzilli, C | 1 |
| Fieschi, C | 1 |
| Sadiq, SA | 1 |
| Rammal, M | 1 |
| Sara, G | 1 |
| Balzer, K | 1 |
| Carrá, A | 1 |
| Onaha, P | 1 |
| Luetic, G | 1 |
| Burgos, M | 1 |
| Crespo, E | 1 |
| Deri, N | 1 |
| Halfon, M | 1 |
| Jaacks, G | 1 |
| López, A | 1 |
| Sinay, V | 1 |
| Vrech, C | 1 |
| Deutsch, F | 1 |
| Cursiefen, S | 2 |
| Toyka, KV | 2 |
| Calabresi, PA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Use of Cellular Stromal Vascular Fraction (cSVF) for Select Multiple Sclerosis, Autoimmune, Inflammatory, and Neurologic Conditions: Clinical Interventional Study of Adverse Events and Clinical Outcomes Using Autologous Stem-Stromal Cells.[NCT02939859] | Phase 1 | 0 participants (Actual) | Interventional | 2018-12-15 | Withdrawn (stopped due to Withdrawn [COVID restrictions prevent patient enrollment or treatment. Clinical Trial facility is being closed due to viral limitations and loss of staff to perform]) | ||
| Evaluation of the Safety and Efficacy of Reduced-intensity Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (AHSCT) in Multiple Sclerosis[NCT03113162] | Phase 1 | 15 participants (Anticipated) | Interventional | 2015-05-29 | Recruiting | ||
| Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders[NCT02021825] | Phase 4 | 50 participants (Anticipated) | Interventional | 2009-03-31 | Recruiting | ||
| Tolerability of Acthar for the Treatment of Multiple Sclerosis Relapses (TAMS)[NCT02258217] | 30 participants (Actual) | Interventional | 2014-06-30 | Completed | |||
| A Randomised, Double Blinded Cross-over Study Comparing the Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis[NCT01149525] | Phase 3 | 59 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Patients completed the ARMS survey after treatment for the new relapse.The ARMS questionnaire (assessing relapses in multiple sclerosis) was developed by a panel of expert MS nurses. Part one consists of 7 questions designed to assess relapse symptoms, impact on activities of daily living, and response to past treatment for MS relapses. Part two consists of 7 questions to evaluate treatment response in terms of relief from symptoms, functioning and tolerability.~The TCS score was calculated only for the time point after treatment of relapse. It was a sum of questions 4 (symptom improvement), 5 (ADL), and 6 (return to previous state of health (RSH)) were evaluated. Scores range from 0 to 30 units, with higher scores representing greater improvement/better functioning." (NCT02258217)
Timeframe: Follow-up visit
| Intervention | score on a scale (Mean) |
|---|---|
| Single Arm | 14.3 |
"Patient history of prior corticosteroid tolerability for the treatment of MS relapses. This will be determined based on patient completion of the ARMS survey at the baseline visit. Also, history of patients from the survey after treatment for the new relapse will be collected.~The ARMS questionnaire (assessing relapses in multiple sclerosis) was developed by a panel of expert MS nurses. Part one consists of 7 questions designed to assess relapse symptoms, impact on activities of daily living, and response to past treatment for MS relapses. Part two consists of 7 questions to evaluate treatment response in terms of relief from symptoms, functioning and tolerability.~ADL scores were calculated from Part 1 (new relapse), question 3 and Part 2 (after treatment of relapse), question 5 both specifically refer to ADL;~Scale: ADL (Activities of Daily Living) Minimum value: 0 Maximum value: 9 Higher scores indicated better functioning/ improvement." (NCT02258217)
Timeframe: baseline visit & follow-up after treatment
| Intervention | score on a scale (Mean) | |
|---|---|---|
| ADL (new relapse) | ADL (after treatment of relapse) | |
| Single Arm | 3.1 | 4.9 |
"Patient history of prior corticosteroid tolerability for the treatment of MS relapses. This will be determined based on patient completion of the ARMS survey at the baseline visit. Also, patients completed the survey after treatment for the new relapse.~The ARMS questionnaire (assessing relapses in multiple sclerosis) was developed by a panel of expert MS nurses. Part one consists of 7 questions designed to assess relapse symptoms, impact on activities of daily living, and response to past treatment for MS relapses. Part two consists of 7 questions to evaluate treatment response in terms of relief from symptoms, functioning and tolerability.~PCS was computed based on the sum of the ADL and RSH questions. The PCS was computed separately for Part 1 (new relapse) and Part 2 (after relapse treatment) and summarized descriptively; Higher scores indicating better functioning/greater improvement. The PCS scores were on a scale of 0 to 20 units." (NCT02258217)
Timeframe: baseline visit & follow-up after treatment
| Intervention | score on a scale (Mean) | |
|---|---|---|
| PCS (New relapse) | PCS (after treatment of relapse) | |
| Single Arm | 7.7 | 9.2 |
"Patient history of prior corticosteroid tolerability for the treatment of MS relapses. This will be determined based on patient completion of the ARMS survey at the baseline visit. Also, patients completed the survey after treatment for the new relapse. The ARMS questionnaire (assessing relapses in multiple sclerosis) was developed by a panel of expert MS nurses. Part one consists of 7 questions designed to assess relapse symptoms, impact on activities of daily living, and response to past treatment for MS relapses. Part two consists of 7 questions to evaluate treatment response in terms of relief from symptoms, functioning and tolerability.~Part 1 (new relapse) & Part 2 (after treatment of new relapse), question 6 were used to calculate RSH;~Scale: RSH (Return to previous health) Minimum value: -1 Maximum value: 10 Higher scores indicating a more complete return to previous state of health." (NCT02258217)
Timeframe: baseline visit & follow-up after treatment
| Intervention | score on a scale (Mean) | |
|---|---|---|
| RSH (new relapse) | RSH (after treatment of new relapse) | |
| Single Arm | 4.6 | 4.4 |
"This scaling score is obtained by performing a neurologic exam with specific attention to eight different neurologic functional systems: visual, pyramidal, cerebellar, bowel and bladder, cerebral, brainstem, sensory and other (10). The score is rated from zero (normal neurologic examination) to ten (death due to MS). This is the standard neurologic disability scale used in clinical trials for the evaluation of disability in patients with MS.~These scores were compared between pre and post phase using paired t-tests." (NCT02258217)
Timeframe: baseline and at follow-up
| Intervention | score on a scale (Median) | |
|---|---|---|
| EDSS score (new relapse) | EDSS score (after treatment of new relapse) | |
| Single Arm | 3.5 | 3.0 |
"Patients who reported a history of poor corticosteroid tolerability will be placed on Acthar and GASE scale will be given to assess tolerability to Acthar.~We listed the number of times a symptom was reported and was attributable to the ACTHAR treatment" (NCT02258217)
Timeframe: 1 week
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Headache | Dry Mouth | Dizziness | Tachycardia, palpitation or arrhythmia | Breathing problems | Abdominal pain | Nausea | Diarrhea | Reduced Appetite | Increased appetite | Difficulties with urination | Skin rash or itching | Tendency to develop bruises | Sweating | Hot flashes | Fatigue, loss of energy | Insomnia, sleeping problems | Nightmares or abnormal dreams | Back pain | Agitation | Irritability | Depressed Mood | Anxiety, fearfulness | Further symptoms | |
| Single Arm | 3 | 1 | 2 | 1 | 1 | 4 | 4 | 4 | 1 | 4 | 2 | 1 | 1 | 1 | 1 | 2 | 8 | 2 | 1 | 6 | 6 | 3 | 1 | 8 |
"The MSIS-29 is a self-reported questionnaire in which MS patients answer a series of 29 questions designed to capture the impact of multiple sclerosis on their life over the past 2 weeks (11). Twenty of the 29 questions assess the physical impact of MS and 9 questions assess the psychological impact of MS.~The psychological impact of MS was compared between pre and post phase using paired t-tests.~The psychological impact of MS was compared between pre and post phase using paired t-tests.~The score was on a scale of 9 to 45 points for MSIS psychological score.~Higher score indicate worse outcome." (NCT02258217)
Timeframe: baseline visit & follow-up after treatment
| Intervention | score on a scale (Mean) | |
|---|---|---|
| MSIS psychological(new relapse) | MSIS psychological(after treatment of new relapse) | |
| Single Arm | 29.4 | 26.3 |
"The MSIS-29 is a self-reported questionnaire in which MS patients answer a series of 29 questions designed to capture the impact of multiple sclerosis on their life over the past 2 weeks (11). Twenty of the 29 questions assess the physical impact of MS.~The physical impact of MS was compared between pre and post phase using paired t-tests. Each question is answered with points ranging from 1 to 5. Higher score indicates worse outcome. The total MSIS physical score ranges from 20 to 100 points with lower points indicating better impact." (NCT02258217)
Timeframe: baseline visit & follow-up after treatment
| Intervention | score on a scale (Median) | |
|---|---|---|
| MSIS physical (new relapse) | MSIS physical (after treatment of new relapse) | |
| Single Arm | 58.5 | 56 |
"The Self-Administered Gerocognitive Exam (SAGE) is designed to detect early signs of cognitive, memory or thinking impairments. It evaluates your thinking abilities and helps physicians to know how well your brain is working.~It consists of 12 questions which are scored at different scales. The final SAGE score is calculated as a sum of these 12 questions and it ranges from 0 to 22.~Higher score indicates better outcome." (NCT02258217)
Timeframe: baseline and follow-up
| Intervention | score on a scale (Median) | |
|---|---|---|
| SAGE (new relapse) | SAGE (after treatment of new relapse) | |
| Single Arm | 21 | 21 |
30 reviews available for mitoxantrone and Acute Relapsing Multiple Sclerosis
| Article | Year |
|---|---|
Is there a change of paradigm towards more effective treatment early in the course of apparent high-risk MS?
Topics: Alemtuzumab; Antineoplastic Agents; Clinical Trials as Topic; Cyclophosphamide; Disease Progression; | 2017 |
Multiple sclerosis, a treatable disease .
Topics: Adjuvants, Immunologic; Alemtuzumab; Crotonates; Demyelinating Diseases; Dimethyl Fumarate; Fingolim | 2017 |
[MODERN APPROACHES TO THE TREATMENT OF MULTIPLE SCLEROSIS (REVIEW AND CLINICAL CASE)].
Topics: Adolescent; Alemtuzumab; Disease Progression; Drug Administration Schedule; Female; Humans; Immunolo | 2018 |
Mitoxantrone for multiple sclerosis.
Topics: Disease Progression; Humans; Immunosuppressive Agents; Mitoxantrone; Multiple Sclerosis; Multiple Sc | 2013 |
Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
Topics: Antibodies, Monoclonal, Humanized; Glatiramer Acetate; Humans; Immunologic Factors; Immunosuppressiv | 2013 |
A network meta-analysis of randomized controlled trials for comparing the effectiveness and safety profile of treatments with marketing authorization for relapsing multiple sclerosis.
Topics: Data Interpretation, Statistical; Disease Progression; Glatiramer Acetate; Interferon beta-1a; Inter | 2013 |
Management of relapsing-remitting multiple sclerosis in Latin America: practical recommendations for treatment optimization.
Topics: Disease Management; Humans; Immunosuppressive Agents; Interferon-beta; Latin America; Mitoxantrone; | 2014 |
Contemporary treatment options for relapsing-remitting multiple sclerosis.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Dimethyl Fumarate; Fumarates; Glatiramer Acetate; Hu | 2014 |
Therapy-related acute leukaemia with mitoxantrone: four years on, what is the risk and can it be limited?
Topics: Antineoplastic Agents; Humans; Leukemia; Mitoxantrone; Multiple Sclerosis; Multiple Sclerosis, Relap | 2015 |
Current management of relapsing-remitting multiple sclerosis.
Topics: Administration, Intravenous; Administration, Oral; Alemtuzumab; Antibodies, Monoclonal, Humanized; C | 2014 |
Update on monitoring and adverse effects of first generation disease modifying therapies and their recently approved versions in relapsing forms of multiple sclerosis.
Topics: Drug Monitoring; Glatiramer Acetate; Humans; Immunologic Factors; Interferon-beta; Mitoxantrone; Mul | 2016 |
Azathioprine in multiple sclerosis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azathioprine; Chemistry, Pharmaceutical; | 2008 |
[Choice of early and escalation treatment options for multiple sclerosis].
Topics: Adjuvants, Immunologic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoc | 2008 |
Early interferon beta treatment in multiple sclerosis: nursing care implications of the BENEFIT study.
Topics: Adjuvants, Immunologic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Clinical Trials a | 2008 |
Immunosuppression followed by immunomodulation.
Topics: Clinical Protocols; Drug Therapy, Combination; Glatiramer Acetate; Humans; Immunologic Factors; Immu | 2009 |
Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Topics: Adult; Cardiotoxins; Controlled Clinical Trials as Topic; Databases, Factual; Female; Humans; Leukem | 2010 |
[2012: Update on diagnosis and treatment of multiple sclerosis].
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Brain; Combined Modality Therapy; Diagnosis | 2012 |
Mitoxantrone in progressive multiple sclerosis: when and how to treat?
Topics: Disability Evaluation; Drug Evaluation; Humans; Mitoxantrone; Multiple Sclerosis, Chronic Progressiv | 2003 |
Current disease-modifying therapies in multiple sclerosis.
Topics: Adjuvants, Immunologic; Analgesics; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azath | 2003 |
[Aggressive multiple sclerosis. Definition and specific therapeutic indication].
Topics: Adjuvants, Immunologic; Adult; Analgesics; Anti-Inflammatory Agents; Clinical Trials as Topic; Diagn | 2004 |
A comparison of the benefits of mitoxantrone and other recent therapeutic approaches in multiple sclerosis.
Topics: Adjuvants, Immunologic; Antioxidants; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Administ | 2004 |
Health outcomes in multiple sclerosis.
Topics: Cost-Benefit Analysis; Glatiramer Acetate; Humans; Immunologic Factors; Interferon-beta; Mitoxantron | 2004 |
[Immunomodulatory therapy in multiple sclerosis].
Topics: Adjuvants, Immunologic; Cognition; Drug Administration Schedule; Glatiramer Acetate; Humans; Immunos | 2004 |
A practical approach to immunomodulatory therapy for multiple sclerosis.
Topics: Glatiramer Acetate; Humans; Immunologic Factors; Interferon-beta; Mitoxantrone; Multiple Sclerosis; | 2005 |
Therapeutic role of mitoxantrone in multiple sclerosis.
Topics: Humans; Mitoxantrone; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2006 |
Multiple sclerosis: advances in understanding, diagnosing, and treating the underlying disease.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Disease Progressio | 2006 |
Management of worsening multiple sclerosis with mitoxantrone: a review.
Topics: Anti-Inflammatory Agents; Clinical Trials, Phase II as Topic; Disease Progression; Humans; Immunosup | 2006 |
[Mitoxantrone (Novantron) in therapy of severe multiple sclerosis. A retrospective study of 15 patients].
Topics: Adult; Antineoplastic Agents; Brain; Disability Evaluation; Dose-Response Relationship, Drug; Drug A | 1999 |
[Escalating immunomodulatory therapy of multiple sclerosis. 1st supplement: December 2000].
Topics: Acute Disease; Adjuvants, Immunologic; Austria; Azathioprine; Diagnosis, Differential; Dose-Response | 2001 |
Considerations in the treatment of relapsing-remitting multiple sclerosis.
Topics: Brain; Clinical Trials as Topic; Disability Evaluation; Glatiramer Acetate; Humans; Immunosuppressiv | 2002 |
16 trials available for mitoxantrone and Acute Relapsing Multiple Sclerosis
| Article | Year |
|---|---|
Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study.
Topics: Adult; Aged; Female; Heart Failure; Humans; Leukemia; Male; Middle Aged; Mitoxantrone; Multiple Scle | 2013 |
Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial.
Topics: Adult; Antineoplastic Agents; Female; Gadolinium; Hematopoietic Stem Cell Transplantation; Humans; I | 2015 |
Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS.
Topics: Adult; Brain; Drug Therapy, Combination; Female; Gadolinium; Glatiramer Acetate; Humans; Immunosuppr | 2008 |
Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial.
Topics: Adult; Brain; Drug Administration Schedule; Drug Therapy, Combination; Female; Gadolinium; Humans; I | 2011 |
Mitoxantrone as rescue therapy in worsening relapsing-remitting MS patients receiving IFN-beta.
Topics: Adult; Antibodies; Brain; Cytokines; Female; Follow-Up Studies; Humans; Interferon-beta; Magnetic Re | 2005 |
A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging.
Topics: Adjuvants, Immunologic; Adult; Antineoplastic Agents; Drug Therapy, Combination; Female; Gadolinium; | 2005 |
Mitoxantrone therapy in rapidly worsening multiple sclerosis.
Topics: Disease Progression; Female; Humans; Male; Middle Aged; Mitoxantrone; Multiple Sclerosis, Chronic Pr | 2005 |
Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial.
Topics: Adult; Antineoplastic Agents; Central Nervous System; Disease Progression; Dose-Response Relationshi | 2005 |
Mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis.
Topics: Adult; Antineoplastic Agents; Dose-Response Relationship, Drug; Echocardiography; Electrocardiograph | 2006 |
Levocarnitine administration in multiple sclerosis patients with immunosuppressive therapy-induced fatigue.
Topics: Acetylcarnitine; Adolescent; Adult; Cyclophosphamide; Fatigue; Female; Humans; Immunosuppressive Age | 2006 |
Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis.
Topics: Adolescent; Adult; Analgesics; Disability Evaluation; Female; Follow-Up Studies; Glatiramer Acetate; | 2006 |
Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis.
Topics: Adolescent; Adult; Age of Onset; Cohort Studies; Female; Humans; Magnetic Resonance Imaging; Male; M | 2007 |
Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients.
Topics: Adult; Antineoplastic Agents; Antiviral Agents; Azathioprine; Brain; Demography; Disability Evaluati | 2008 |
Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety.
Topics: Adult; Alkylating Agents; Antineoplastic Agents; Blood Cell Count; Cyclophosphamide; Disease Progres | 2008 |
Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina.
Topics: Adult; Argentina; Disability Evaluation; Female; Glatiramer Acetate; Humans; Immunologic Factors; In | 2008 |
Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis.
Topics: Adolescent; Adult; Antineoplastic Agents; Drug Therapy, Combination; Female; Glatiramer Acetate; Hum | 2008 |
40 other studies available for mitoxantrone and Acute Relapsing Multiple Sclerosis
| Article | Year |
|---|---|
Ten-year follow-up after mitoxantrone induction for early highly active relapsing-remitting multiple sclerosis: An observational study of 100 consecutive patients.
Topics: Follow-Up Studies; Humans; Mitoxantrone; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive | 2022 |
Escalation Versus Induction/High-Efficacy Treatment Strategies for Relapsing Multiple Sclerosis: Which is Best for Patients?
Topics: Alemtuzumab; Cladribine; Humans; Immunosuppressive Agents; Mitoxantrone; Multiple Sclerosis; Multipl | 2023 |
Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.
Topics: Humans; Mitoxantrone; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosi | 2020 |
Clinical follow-up of 411 patients with relapsing and progressive multiple sclerosis 10 years after discontinuing mitoxantrone treatment: a real-life cohort study.
Topics: Adult; Cohort Studies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Mitoxantrone; Multiple | 2018 |
Cerebrospinal fluid NCAM levels are modulated by disease-modifying therapies.
Topics: Adult; Biomarkers; CD56 Antigen; Enzyme-Linked Immunosorbent Assay; Female; Fingolimod Hydrochloride | 2019 |
Safety and efficacy of mitoxantrone in pediatric patients with aggressive multiple sclerosis.
Topics: Adolescent; Child; Female; Humans; Immunosuppressive Agents; Male; Mitoxantrone; Multiple Sclerosis, | 2014 |
Alemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational study.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cohort Studies; Disabi | 2015 |
Fatal Acute Myeloid Leukemia With 11q23 MLL Gene Rearrangement Following Mitoxantrone Treatment in a Case of Childhood-onset Multiple Sclerosis.
Topics: Adolescent; Chromosomes, Human, Pair 11; Fatal Outcome; Female; Gene Rearrangement; Histone-Lysine N | 2015 |
Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone.
Topics: Adult; Biomarkers; Female; Follow-Up Studies; Humans; Immunologic Factors; Male; Membrane Glycoprote | 2016 |
How effective is natalizumab as second-line treatment for multiple sclerosis in daily clinical praxis?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Clinical Trials, Phase III as Topic; Drug | 2009 |
Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study.
Topics: Adolescent; Adult; Anaphylaxis; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Denmark; | 2009 |
Dose-dependent melanonychia by mitoxantrone.
Topics: Adult; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Hyperpigmentation; I | 2009 |
Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Child; Cohort Studies; Fem | 2009 |
Magnetic resonance evidence of cerebellar cortical pathology in multiple sclerosis.
Topics: Adolescent; Adult; Antineoplastic Agents; Atrophy; Cerebellum; Disability Evaluation; Female; Humans | 2010 |
[Combined therapy of aggressive remitted multiple sclerosis with mitoxantrone in combination with copaxone].
Topics: Adjuvants, Immunologic; Adult; Analgesics; Disease Progression; Drug Therapy, Combination; Female; F | 2009 |
Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis.
Topics: Adult; Antibodies, Neutralizing; Antineoplastic Agents; Central Nervous System; Disability Evaluatio | 2010 |
Immunotherapy and multiple sclerosis: The devil is in the details.
Topics: Controlled Clinical Trials as Topic; Humans; Immunotherapy; Mitoxantrone; Multiple Sclerosis; Multip | 2010 |
[Diagnosis and therapy in multiple sclerosis].
Topics: Adult; Analgesics; Antiviral Agents; Central Nervous System; Diagnosis, Differential; Evoked Potenti | 2010 |
[Clinical, radiographic, prognostic and therapeutic aspects of demelinating disease with tumefactive demyelinating lesions].
Topics: Adolescent; Case-Control Studies; Comorbidity; Disease Progression; Drug Therapy, Combination; Evoke | 2011 |
Comparative study of mitoxantrone efficacy profile in patients with relapsing-remitting and secondary progressive multiple sclerosis.
Topics: Adolescent; Adult; Aged; Disability Evaluation; Disease Progression; Female; Humans; Immunosuppressi | 2010 |
Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study.
Topics: Adult; Amenorrhea; Female; France; Heart Failure; Humans; Immunologic Factors; Leukemia; Male; Middl | 2011 |
Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Fingolimod Hydrochloride; Glatiramer Acetat | 2011 |
Cerebrospinal fluid biomarkers of β-amyloid metabolism in multiple sclerosis.
Topics: Adult; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Antibodies, Monoclonal, Humanized; Bio | 2013 |
Serial gadolinium-enhanced MRI in acute attack of multiple sclerosis treated with plasma exchange.
Topics: Acute Disease; Adult; Anti-Inflammatory Agents; Antineoplastic Agents; Gadolinium; Humans; Magnetic | 2003 |
Predictive parameters of mitoxantrone effectiveness in the treatment of multiple sclerosis.
Topics: Adult; Disability Evaluation; Disease Progression; Female; Humans; Magnetic Resonance Imaging; Male; | 2004 |
The application of enhanced parallel gatekeeping strategies.
Topics: Analgesics; Computer Simulation; Data Interpretation, Statistical; Gatekeeping; Humans; Mitoxantrone | 2005 |
Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone.
Topics: Adult; Cohort Studies; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Mitoxant | 2005 |
Multiplicity adjustment for multiple endpoints in clinical trials with multiple doses of an active treatment.
Topics: Analgesics; Clinical Trials, Phase III as Topic; Computer Simulation; Data Interpretation, Statistic | 2005 |
[Mitoxantrone as induction therapy in aggressive relapsing remitting multiple sclerosis: a descriptive analysis of 100 consecutive patients].
Topics: Adult; Age of Onset; Analgesics; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studie | 2006 |
[Escalating immunomodulatory therapy of multiple sclerosis. Update (September 2006)].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Dose-Response Relationship, Drug; Drug Ad | 2006 |
[Long-term application of the multiple sclerosis functional composite test in Debrecen, Hungary].
Topics: Adult; Arm; Azathioprine; Cognition; Disability Evaluation; Female; Glatiramer Acetate; Hand Strengt | 2006 |
3-methylcrotonyl-CoA carboxylase deficiency and severe multiple sclerosis.
Topics: Adjuvants, Immunologic; Adolescent; Analgesics; Brain; Carbon-Carbon Ligases; Female; Humans; Interf | 2007 |
Clinical follow-up of 304 patients with multiple sclerosis three years after mitoxantrone treatment.
Topics: Antineoplastic Agents; Disability Evaluation; Female; Follow-Up Studies; Glatiramer Acetate; Humans; | 2007 |
Multiple sclerosis in Pakistan.
Topics: Adolescent; Adult; Antineoplastic Agents; Female; Humans; Immunologic Factors; Immunosuppressive Age | 2007 |
[Recent advances in the pathogenesis and immunotherapy of multiple sclerosis].
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Cerebr | 2007 |
[Mitoxantrone for the treatment of Japanese patients with multiple sclerosis].
Topics: Adult; Disability Evaluation; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Mitox | 2007 |
Mitoxantrone treatment in multiple sclerosis: a 5-year clinical and MRI follow-up.
Topics: Adult; Female; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Mitoxantron | 2007 |
Chronic myeloid leukemia associated with mitoxantrone treatment in a patient with MS.
Topics: Adult; Antineoplastic Agents; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mito | 2008 |
[Nursing care of patients with basic multiple sclerosis therapy: preventing relapses].
Topics: Antineoplastic Agents; Community Health Nursing; Drug Administration Schedule; Education, Nursing, C | 2007 |
Escalating immunotherapy with mitoxantrone in patients with very active relapsing-remitting or progressive multiple sclerosis.
Topics: Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Immunosuppres | 2000 |